All Outputs (3)

Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT) (2019)
Journal Article
Young, B., Bedford, L., das Nair, R., Gallant, S., Littleford, R., Robertson, J. F., …ECLS Study Team. (2020). Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT). Journal of Evaluation in Clinical Practice, 26(3), 893-902. https://doi.org/10.1111/jep.13230

Rationale, aims, and objectives: High response rates to research questionnaires can help to ensure results are more representative of the population studied and provide increased statistical power, on which the study may have been predicated. Improvi... Read More about Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT).

A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening (2019)
Conference Proceeding
Figueredo, G. P., Shi, P., Parkes, A. J., Evans, K., Garibaldi, J. M., Negm, O., …Robertson, J. (2019). A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening. In 2019 IEEE Congress on Evolutionary Computation (CEC) (95-102). https://doi.org/10.1109/CEC.2019.8790316

Current methods to identify cutoff values for tumour-associated molecules (antigens) discrimination are based on statistics and brute force. These methods applied to cancer screening problems are very inefficient, especially with large data sets with... Read More about A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening.

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer (2019)
Journal Article
Robertson, J. F. R., Jiang, Z., Di Leo, A., Ohno, S., Pritchard, K. I., Ellis, M., …Campbell, C. (2019). A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer, 26(6), 703-711. https://doi.org/10.1007/s12282-019-00973-4

Background Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). Methods Meta-analysis of randomized controlled... Read More about A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.